Product Images Bortezomib

This is a comparison study between the survival rates of patients with relapsed multiple myeloma treated with Bortezomib and Dexamethasone. The figure shows the overall survival percentage at different time points, with Bortezomib having a higher survival rate compared to Dexamethasone. The text also provides a statistical significance level of p<0.05 for the difference between the two treatments. The number of patients remaining after a certain time point is also indicated.*

This is a chart displaying the results of a Log Rank Test for two treatments, "VERCAP" and "R-CHOP". The percentage of patients and their survival rates are listed across different time intervals, ranging from 0 to 68 months. Data was likely collected on the number of patients who survived the treatment over the course of the study, with "VERCAP" having a higher survival rate overall.*

The given text seems to be a graph that shows the survival rate of subjects with two different treatments over time (in months) from randomization. The two treatments compared are VcR-CAP and R-CHOP. The text indicates that after 100% of subjects started, the survival rate of those who received VcR-CAP was higher than those who received R-CHOP. The Hazard Ratio (HR) was 0.66 (with a 95% Confidence Interval of 0.51 - 0.85). However, since only numeric characters and some special characters are present in the text, it is unclear what the underlying conditions or diseases were, and what the units of measurement were.*

This appears to be a description of a medication called Bortezomib for injection, which is used for subcutaneous or intravenous use for cytotoric purposes. It comes in a vial containing 3.5mg of the medication, and must be stored at 20-25°C. Instructions for reconstitution are provided for both subcutaneous and intravenous usage. The NDC number is 63323-82110.*

This is a prescription drug with the NDC code 63323-821-10. The drug is Bortezomib, a cytotoxic agent used for injection as a single dose. Each vial contains 3.5mg Bortezomib and 35mg mannitol. The drug must be discarded if unused, and should be stored at temperatures between 20°C to 25°C. The container is sterile and does not contain natural rubber latex. Detailed dosage information can be found in the package insert.*